Find Clinical Trials | Cedars-Sinai

394 results found

Melanoma

PF-07799544 as a Single Agent and in Combination With Other Targeted Agents in BRAF-Mutant Melanoma and Other Solid Tumors

This study focuses on people who have melanoma (skin cancer) or other cancer with a specific change in the BRAF gene (BRAF alteration) and whose cancer has grown or spread. The study will explore the ...

Other

Becton, Dickinson and Company_IDS-23BACT002_BD Blood Culture Study

This is a prospective, multi-center (approximately 6 sites, at least 4 in the U.S. and 2 in the EU) study that will be conducted to evaluate the performance of the BACTEC FXI culture system and ...

Movement Disorders

BIIB122 in Participants With LRRK2-Associated Parkinson's Disease

The purpose of this study is to evaluate whether an experimental drug called BIIB122 is safe and tolerable in LRRK2-associated Parkinson’s disease (LRRK2-PD) patients. LRRK2-PD is a form of Parkinson’s disease caused by genetic mutation(s) ...

Other Hematopoietic

MK-2140 in Combination With R-CHP Versus R-CHOP in Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate the safety and effectiveness of the combination of an experimental drug called zilovertamab vedotin (MK-2140) plus a series of cancer drugs (R-CHP) in treating people with diffuse ...

Melanoma

Regeneron, R3767-ONC-2466, Ph2, open label, Melanoma, Fianlimab Plus Cemiplimab

Primary -Assess Overall Survival (OS) of patients with melanoma treated with Fianlimab Plus Cemiplimab in Expansion Cohorts from R3767-ONC-1613 Secondary -Assess Progression-Free Survival (PFS) -Assess Objective Response Rate (ORR) -Assess Duration of Response (DOR) -Assess Disease Control Rate (DCR) ...